ARTA
STML

A.R.T. Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

A.R.T. Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,819
Closed -$285K – 1255
2019
Q4 		$285K Buy
+26,819
New +$266K 0.01% 1040
2019
Q3 		– Sell
-49,172
Closed -$753K – 1883
2019
Q2 		$753K Buy
49,172
+36,700
+294% +$531K 0.04% 578
2019
Q1 		$160K Buy
+12,472
New +$141K 0.01% 1110
2018
Q4 		– Sell
-21,497
Closed -$356K – 1832
2018
Q3 		$356K Sell
21,497
-9,131
-30% -$146K 0.02% 976
2018
Q2 		$491K Buy
+30,628
New +$547K 0.02% 930
2018
Q1 		– Sell
-10,238
Closed -$159K – 1884
2017
Q4 		$159K Sell
10,238
-5,800
-36% -$77.6K 0.01% 1203
2017
Q3 		$178K Sell
16,038
-4,300
-21% -$40.4K 0.01% 1154
2017
Q2 		$187K Sell
20,338
-14,700
-42% -$123K 0.01% 1176
2017
Q1 		$299K Buy
+35,038
New +$319K 0.01% 1003
2016
Q3 		– Sell
-12,061
Closed -$81K – 1370
2016
Q2 		$81K Buy
+12,061
New +$76.1K ﹤0.01% 1232
2016
Q1 		– Sell
-16,261
Closed -$102K – 1774
2015
Q4 		$102K Sell
16,261
-5,418
-25% -$44K ﹤0.01% 1326
2015
Q3 		$191K Sell
21,679
-10,976
-34% -$115K 0.01% 1175
2015
Q2 		$384K Buy
+32,655
New +$453K 0.01% 1095
2013
Q3 		– Sell
-20,184
Closed -$481K – 1577
2013
Q2 		$481K Buy
+20,184
New +$321K 0.02% 890

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

A.R.T. Advisors's STML Position: Q1 2020 in Review

A.R.T. Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 26,819 shares — an estimated $285K sold.

A.R.T. Advisors first reported a position in STML in Q2 2013 and held it in 14 quarters. The position peaked at $753K in Q2 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • A.R.T. Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 26,819 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $285K.
  • A.R.T. Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
  • A.R.T. Advisors's Stemline Therapeutics, Inc. position peaked at $753K in Q2 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.